OrthoLogic to Webcast Conference Call Discussing Second Quarter 2005 Financial Results on July 26, 2005

OrthoLogic to Webcast Conference Call Discussing Second Quarter
2005 Financial Results on July 26, 2005 


TEMPE, Ariz., July 19  /PRNewswire-FirstCall/ -- OrthoLogic Corp. (NASDAQ:OLGC)
announced today that it will release financial and operating results for the
second quarter of 2005 on Tuesday, July 26, 2005 after the U.S. markets close.

Management will host a conference call and webcast the same day at 4:30 p.m.
EDT (1:30 p.m. PDT).  To access the call, participants may dial 800-289-0544
(domestic) or 913-981-5533 (international) and provide the access code 6064597.

A replay of the call will be available beginning July 26, 2005, at 7:30 p.m.
EDT until August 25, 2005, at 12:59 a.m. EDT.  To access the replay, please
dial 888-203-1112 (domestic) or 719-457-0820 (international) and provide the
access code 6064597.

Additionally, the conference call will be webcast on the Investor Relations
section of the Company's website, http://www.orthologic.com/, and can be
accessed by clicking here: OrthoLogic 2Q05 Earnings Webcast.

About OrthoLogic Corp.

OrthoLogic is a drug-development company focused on commercializing several
potential therapeutics comprising the Chrysalin(R) Product Platform, a series
of product candidates aimed at treating traumatic and chronic orthopedic
indications in bone and soft tissue as well as cardiovascular repair and wound
healing.  All of these potential products are based on the Chrysalin synthetic
peptide, also known as TP508.

OrthoLogic owns an exclusive license for all worldwide medical indications for
the peptide, and is actively pursuing five orthopedic indications for
Chrysalin.  These include fracture repair and spine fusion, which are in human
clinical trials, and cartilage defect repair, which is in late-stage
preclinical trials.  Ligament and tendon repair indications are in the
preclinical studies stage.  In non-orthopedic areas, a human clinical trial for
chronic diabetic ulcers has been completed.  OrthoLogic's product development
pipeline also includes Chrysalin-based product candidates for dental bone
formation and myocardial revascularization.

For more information, please visit the company's Web site:
http://www.orthologic.com/. 

DATASOURCE: OrthoLogic Corp.



CONTACT:  Sherry A. Sturman Chief Financial Officer of OrthoLogic Corp.,

[phone]; or Melanie Friedman of Stern Investor Relations, Inc.,

[phone], for OrthoLogic Corp.



Web site:  http://www.orthologic.com/ 

Copyright